

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Bladder Cancer and Renal Cell Carcinoma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following combinations are being compared to sunitinib as first-line therapy for patients with advanced renal cell carcinoma (RCC) in the Phase III CLEAR trial?
 - a. Lenvatinib with everolimus or pembrolizumab
 - b. Lenvatinib with nivolumab or pembrolizumab
 - c. Tivozanib with everolimus or pembrolizumab
 - d. Pazopanib with nivolumab or pembrolizumab
2. The ongoing CONTACT-03 trial is evaluating the safety and efficacy of which multikinase inhibitor alone or in combination with atezolizumab for patients with inoperable, locally advanced or metastatic RCC who have experienced radiographic tumor progression during or after treatment with an immune checkpoint inhibitor?
 - a. Lenvatinib
 - b. Pazopanib
 - c. Cabozantinib
 - d. Bevacizumab
3. The Phase III JAVELIN Bladder 100 trial assessing the efficacy of maintenance therapy with avelumab in addition to best supportive care (BSC) versus BSC alone for patients with advanced bladder cancer who respond to front-line platinum-based chemotherapy demonstrated which overall survival outcome with avelumab/BSC?
 - a. A significant improvement
 - b. No improvement
4. Which of the following conditions are commonly associated with erdafitinib therapy for patients with metastatic urothelial bladder carcinoma?
 - a. Tinnitus and neurotoxicity
 - b. Ocular disorders and hyperphosphatemia
 - c. Proteinuria and hypertension
 - d. Increased appetite and hypertension